[의학신문·일간보사=김영주 기자]Yuhan Corporation (CEO, Wook-Je Cho) announced on the 23rd that it was registered as the 2nd largest shareholder by investing an additional 10 billion won in April Bio, which has Serum Albumin Fragment Associated (SAFA) technology.
Established in 2013, April Bio is an antibody that develops global innovative new drugs in a variety of therapeutic areas using its own human antibody library (HuDVFab) technology and SAFA (Serum Albumin Fragment Associated), a sustained platform technology that can increase the half-life of antibody fragment utilization. It is a new drug company.
April Bio is preparing for phase 1 clinical trial in the United States this year, APB-A1, a preclinical inflammatory autoimmune disease treatment (IL-18 target), APB-R3, male infertility treatment (FSH target) APB -R2, etc. are being developed.
Recently, April Bio decided to issue a paid-in capital increase of 10 billion won worth to a third party for Yuhan Corporation. In 2020, it attracted 18 billion won worth of Series B investment, and at that time, Yuhan Corporation as a strategic investor (SI) invested 3 billion won in April Bio to acquire a 4.89% stake.
Since then, Yuhan Corporation and April Bio signed a “Joint Research New Drug Development Business Agreement” to strengthen research cooperation, and through additional investments, the two companies are further strengthening the partnership.
Reporter Kim Young-joo [email protected]
<저작권자 © 의학신문, 무단 전재 및 재배포 금지>